Two for two: GSK follows Pfizer, secures adcomm thumbs-up for RSV vaccine in older adults
FDA’s vaccine advisory committee gave a thumbs-up to GSK’s RSV vaccine candidate on Wednesday, marking the end of a two-day adcomm where experts gave their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
